Sprint Bioscience, a Stockholm, Sweden-based company developing oncology therapeutics targeting cancer metabolism, has raised a funding of undisclosed amount.
The company intends to use the capital to continue to build a pipeline of drug discovery projects within cancer metabolism.
Co-founded by CEO Dr. Anders Åberg, Sprint Bioscience has developed a fragment-based drug discovery (FBDD) platform that uses structural information on the target protein together with modern synthetic chemistry to develop perfect-fit lead structures. utilizes structural information on the target protein together with modern synthetic chemistry to quickly develop perfect-fit lead structures. The company aims to out-license or collaborate at an early stage of drug discovery to ensure that projects are developed with a focus on current and relevant market needs.